MENS (Jyong Biotech) LT-Debt-to-Total-Asset: 0.49 (As of Dec. 2025)


MENS Jyong Biotech Ltd MENS
10 GF Score
Price $2.22
! 3 Warning Signs
View Full Analysis

What is Jyong Biotech LT-Debt-to-Total-Asset?

Jyong Biotech MENS +6.47% 10 LT-Debt-to-Total-Asset is 0.49 as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Jyong Biotech's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.49.

Jyong Biotech's long-term debt to total assets ratio declined from Dec. 2024 (1.68) to Dec. 2025 (0.49). It may suggest that Jyong Biotech is progressively becoming less dependent on debt to grow their business.

Jyong Biotech  (NAS:MENS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Jyong Biotech LT-Debt-to-Total-Asset Related Terms

Jyong Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Jyong Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jyong Biotech LT-Debt-to-Total-Asset Chart

Jyong Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.70 0.74 1.04 1.68 0.49

Jyong Biotech Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 1.04 1.51 1.68 0.33 0.49
MENS
10GF Score
Jyong Biotech Ltd MENS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jyong Biotech LT-Debt-to-Total-Asset Calculation

Jyong Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=10.186/20.778
=

Jyong Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=10.186/20.778
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.49 mean?
Jyong Biotech (MENS) has a LT-Debt-to-Total-Asset of 0.49 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Jyong Biotech and its competitors.
Is Jyong Biotech's LT-Debt-to-Total-Asset too high?
Jyong Biotech's current LT-Debt-to-Total-Asset is 0.49. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's LT-Debt-to-Total-Asset compare to ENLV and CNTB?
Jyong Biotech's LT-Debt-to-Total-Asset of 0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Jyong Biotech and its competitors. Jyong Biotech's current LT-Debt-to-Total-Asset is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current LT-Debt-to-Total-Asset of 0.49. The current LT-Debt-to-Total-Asset is 0.49. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Jyong Biotech (MENS), the current LT-Debt-to-Total-Asset is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jyong Biotech Business Description

Address Xintai 5th Road, 23F-3, No. 95, Section 1, Xizhi district, New Taipei, TWN, 221
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score

Get the complete analysis for MENS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price